High bioactivity proteins for antibody drug conjugate (ADC) development

 | Post date: 2021/10/19 | 

Antibody-drug conjugates (ADCs) can be described as highly targeted biopharmaceutical drugs that integrate monoclonal antibodies specific to surface antigens and highly potent anti-cancer agents connected through a chemical linker while protecting normal cells from damage.

This possibly reduces the side effects linked to cancer therapy. There are nine approved drugs commercially available on the market at present.

Hot targets

High bioactivity proteins for antibody drug conjugate (ADC) development

Image Credit: ACROBiosystems

ACROBiosystems has come up with a range of products, including various species and tags for a range of hot targets, which are considered to be appropriate for immune, SPR, antibody screening, cell activity detection and other experiments.

ACROBiosystems is devoted to helping users in drug development, and all SPR and BLI protocols are freely available. In addition, over-expressed cell lines and kit products are coming soon.

Product features

High purity verified by MALS

The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80–95 kDa verified by SEC-MALS.

The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80–95 kDa verified by SEC-MALS. Image Credit: ACROBiosystems

The purity of Human EGF R, His Tag (Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90–115 kDa verified by SEC-MALS

The purity of Human EGF R, His Tag (Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90–115 kDa verified by SEC-MALS. Image Credit: ACROBiosystems

High affinity validated by SPR&BLI

Trastuzumab captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

Trastuzumab captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay. Image Credit: ACROBiosystems

Loaded Trastuzumab on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay.

Loaded Trastuzumab on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay. Image Credit: ACROBiosystems

Cetuximab captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.

Cetuximab captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay. Image Credit: ACROBiosystems

Loaded Cetuximab on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay.

Loaded Cetuximab on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay. Image Credit: ACROBiosystems
https://www.news-medical.net/High-bioactivity-proteins-for-antibody-drug-conjugate-(ADC)-development




CAPTCHA

View: 314 Time(s)   |   Print: 7 Time(s)   |   Email: 0 Time(s)   |   0 Comment(s)


© 2021 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb